The UK Pouchitis therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Pouchitis is an inflammatory condition of the ileal pouch. It happens when the ileal pouch reservoir becomes inflamed or irritated. Pouchitis mainly occurs in a patient who has undergone ileal pouch-anal anastomosis (IPAA), a surgical procedure for removing the rectum and the large intestine. About half of the number of patients who undergo this surgery develop pouchitis at least once in their lifetime. Every year, up to 40% of patients who undergo IPAA surgery develop pouchitis. However, the exact cause of pouchitis has not yet been determined.
Pouchitis has been observed occurring among patients suffering from ulcerative colitis or some other form of colitis, and also rarely among patients with genetic conditions (familial adenomatous polyposis), in which many polyps are formed in the colon. Other factors responsible for the development of pouchitis include backwash ileitis, long-term usage of non-steroidal anti-inflammatory drugs (NSAIDs), increased number of platelets, smoking, and health conditions such as diabetes or heart disease. Common symptoms of pouchitis include tenesmus, straining during defecation, blood in stool, seepage of waste matter while asleep, incontinence, tail bone pain, abdominal cramp, and increased frequency in night-time bowel movements.
Market Growth Drivers
The UK pouchitis treatment market is expected to expand at a significant CAGR during the forecast period. However, a few potential drugs have been approved, such as Alicaforsen; the molecule developed by Atlantic Pharmaceuticals Limited. Rise in the incidence and prevalence of ulcerative colitis, increase in the number of ileal pouch-anal anastomosis procedures, long-term usage of non-steroidal anti-inflammatory drugs, and growth in the geriatric population are the key factors driving the pouchitis treatment market.
Rise in the number of patients undergoing ileal pouch-anal anastomosis, increase in R&D expenditure, ongoing intensive research on bowel complications, and well-established healthcare infrastructure, among other factors, contribute to the growth of the pouchitis treatment market.
However, the disappointing results of promising pipeline molecules and stringent government regulations are anticipated to hamper the growth of the pouchitis treatment market during the forecast period.